Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual panel discussion at the JonesTrading Virtual Radiopharma Day on Tuesday, October 29, 2024 at 2:35 p.m. ET.
U.S. Food and Drug Administration (FDA) recently granted Fast Track designation for Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer
New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.
Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
Newly elected members of Board of Directors consist of internationally merited business and clinical leaders
Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer
IND clearance is now obtained for both lead indications for Radspherin®
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.